Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ICCC
BuyPremium GrowerImmuCell Corporation · Healthcare · United States · $90M · Avg Vol: $264K/d
74
StockRankGet insider-trade alerts
Q
61
V
41
M
67
P/E (TTM)
141.4x
ROE
2.6%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 18.6M | 17.5M | 26.5M | 27.6M | 14.2% | 30.7M |
| EPS | -0.32 | -0.75 | -0.26 | -0.12 | — | 0.07 |
| Shares | 7.7M | 7.8M | 9.0M | 9.0M | +16.8% | 9.1M |
| Debt | 12.5M | 16.7M | 15.1M | 13.2M | 1.9% | 12.4M |
| Equity | 30.4M | 25.0M | 27.5M | 27.1M | -3.8% | — |
| Op CF | -1.5M | -4.7M | 0.4M | 2.5M | 591.6% | 5.9M |
| Inv CF | -4.0M | -1.9M | -0.5M | -1.2M | — | — |
| Fin CF | 1.1M | 1.8M | 2.9M | -1.2M | — | — |
Loading 1Y...
PRICE (1Y)-10.3%
SMA 50SMA 200
Close
$9.92
RSI (14)
42.3
52W High
$12.10
From 52W High
0.8%
SCORE BREAKDOWN
Quality
61
ROIC
-0.2%44.3
ROE
2.6%49.6
GP/Assets
29.1%62.5
Op. Margin
26.9%89.6
FCF/Assets
7.9%81.0
Piotroski
783.9
Int. Cover
-0.2x35.5
D/E Ratio
0.40x34.3
Current Ratio
4.75x70.6
Value
41
P/E (TTM)
141.4x5.5
EV/EBITDA
13.3x55.4
P/FCF
26.7x51.8
P/B
2.9x47.9
P/S
2.9x57.5
Div Yield
—N/A
Momentum
67
52W High %
82%72.4
RS 6M
37%88.6
SMA 50/200
1.31x93.7
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
-257%2.0
Q Growth
266%94.2
FUNDAMENTALS
Market Cap
$90M
P/E (Forward)
-90.0x
Gross Margin
40.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ICCC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ICCC | ImmuCell Corporation(you) | $90M | 74 | Buy |
| SPRO | Spero Therapeutics, Inc. | $70M | 67 | Buy |
| RLYB | Rallybio Corporation | $89M | 53 | Hold |
| ORMP | Oramed Pharmaceuticals Inc. | $209M | 80 | Strong Buy |
| AGEN | Agenus Inc. | $345M | 75 | Buy |
| FBIO | Fortress Biotech, Inc. | $92M | 45 | Hold |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 97 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $656M | 73 | Buy |
| BSEM | BioStem Technologies, Inc. | $63M | 39 | Hold |
| XLO | Xilio Therapeutics, Inc. | $59M | 38 | Hold |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.3%